Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328771 | 0.89 | HTR2A (0.36) | HTR2AHTR2CP2RX7FPR2PROKR1 | |
| SCHEMBL6336004 | 0.88 | P2RX7 (0.39) | HTR2AHTR2CP2RX7PGR | |
| SCHEMBL6326138 | 0.88 | HTR2A (0.38) | HTR2AHTR2CP2RX7FPR2PROKR1 | |
| SCHEMBL6325660 | 0.85 | OPRL1 (0.42) | HTR2AHTR2CFPR2PROKR1 | |
| SCHEMBL6333754 | 0.85 | P2RX7 (0.41) | HTR2AP2RX7 | |
| SCHEMBL6329598 | 0.84 | HTR2A (0.39) | HTR2AHTR2CP2RX7PGR | |
| SCHEMBL6331104 | 0.84 | P2RX7 (0.37) | HTR2AHTR2CP2RX7 | |
| SCHEMBL6328573 | 0.83 | NMT2 (0.41) | HTR2AHTR2CP2RX7PGR | |
| SCHEMBL6330799 | 0.83 | P2RX7 (0.39) | HTR2AP2RX7 | |
| SCHEMBL6328298 | 0.83 | HTR2A (0.39) | HTR2AHTR2CP2RX7PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | HTR2A 2694/4885HTR2C 3759/4885P2RX7 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.